^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Vulvar Cancer

    1d
    A rare case of multifocal vulvar carcinoma of mammary gland type (AMGT) with mucinous features: Differential diagnosis and literature review. (PubMed, Gynecol Oncol Rep)
    Immunohistochemistry is critical in identifying the "mammary-like" phenotype of AMGT and excluding other primary and metastatic tumors of vulva. The unique biologic profile of AMGT dictates a treatment strategy distinct from other primary vulvar tumors.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • GATA3 (GATA binding protein 3)
    5d
    Primary Apocrine Adenocarcinoma of the Vulva: A Report of a Rare Case. (PubMed, Cureus)
    This profile supported the diagnosis of primary vulvar apocrine adenocarcinoma, allowing for appropriate surgical management and successful excision of the lesion. This case highlights the diagnostic complexity of vulvar adenocarcinomas and underscores the importance of systematic clinicopathologic evaluation, particularly in patients with a history of malignancy.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
    |
    AR positive • ER negative
    7d
    ANTARES: Agnostic Therapy in Rare Solid Tumors (clinicaltrials.gov)
    P2, N=28, Recruiting, Instituto do Cancer do Estado de São Paulo | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker • Pan tumor
    |
    FH (Fumarate Hydratase) • MITF (Melanocyte Inducing Transcription Factor)
    |
    Opdivo (nivolumab)
    7d
    HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (clinicaltrials.gov)
    P1, N=32, Completed, Baylor College of Medicine | Active, not recruiting --> Completed | Trial completion date: Oct 2033 --> Jan 2026
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    8d
    Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (clinicaltrials.gov)
    P=N/A, N=72, Completed, Travera Inc | Recruiting --> Completed | N=200 --> 72 | Trial completion date: Jul 2028 --> Mar 2026 | Trial primary completion date: Jul 2027 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    9d
    IGNITE-V: Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=58, Recruiting, Hamilton Health Sciences Corporation | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Nov 2026 | Trial primary completion date: Sep 2025 --> May 2026
    Enrollment open • Trial completion date • Trial primary completion date
    10d
    Complete and durable response to trastuzumab deruxtecan in HER2-amplified invasive vulvar adenocarcinoma: A case report. (PubMed, Gynecol Oncol Rep)
    With subsequent trastuzumab deruxtecan (T-Dxd) treatment, she achieved a complete and durable response and remains with no evidence of disease after one year of follow-up. This report underscores the potential utility of HER2-directed therapy in select cases of vulvar carcinoma and emphasizes the importance of molecular profiling in rare gynecologic neoplasms.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    14d
    Squamous Precursor Lesions of the Vulva: A Practical Approach. (PubMed, Dermatol Clin)
    Accurate classification is essential, as prognosis, progression risk, and recurrence rates differ among subgroups. Diagnosis relies on integrated assessment of clinical presentation, histopathology, and immunophenotype, particularly p16 and p53 expression.
    Review • Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    15d
    Adenocarcinoma of Mammary Gland Type of the Vulva. (PubMed, Int J Surg Pathol)
    Given the rarity of the tumor, it is crucial to distinguish it from morphological mimics to inform appropriate patient management. Treatment approaches are typically based on protocols for primary breast cancer, given the histological and biological similarities between these tumors and breast tissue.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • AR (Androgen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDK4 (Cyclin-dependent kinase 4) • KRT7 (Keratin-7) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • TRPS1 (Transcriptional Repressor GATA Binding 1)
    |
    HER-2 amplification • TP53 Y220C
    27d
    Nectin-4 expression in vulvar squamous cell carcinoma. (PubMed, Virchows Arch)
    One potential target for the ADC Enfortumab Vedotin (EV) is Nectin-4...Nectin-4 could be a potential target in the therapy of women with VSCC. Further (pre-)clinical data is needed to evaluate the use of EV in therapy of women with VSCC.
    Journal • IO biomarker
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)
    29d
    CXCL8 Promotes the Progression of Vulvar Squamous Cell Carcinoma and Serves as a Potential Prognostic Biomarker. (PubMed, Int J Womens Health)
    Transcriptomic profiling explored CXCL8-activated pathways, including cytokine-cytokine receptor interaction, transforming growth factor (TGF)-β signaling pathway, and tryptophan metabolism. These findings highlight CXCL8 as a potential prognostic biomarker for VSCC and underscore its role in driving tumor proliferation, providing a rationale for targeting CXCL8 in vulvar cancer therapy.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    30d
    Reiki-Brachy: Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies (clinicaltrials.gov)
    P2, N=68, Recruiting, University of Utah | Trial primary completion date: Feb 2026 --> Jun 2026
    Trial primary completion date